search
Back to results

Matrix Therapy And Bacterial Keratitis (CACICOL)

Primary Purpose

Bacterial Keratitis

Status
Unknown status
Phase
Not Applicable
Locations
France
Study Type
Interventional
Intervention
RGTA OTR4120 (CACICOL20)
physiological salt solution
Sponsored by
University Hospital, Clermont-Ferrand
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Bacterial Keratitis focused on measuring Bacterial keratitis, OTR4120, Matrix therapy

Eligibility Criteria

18 Years - undefined (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

  • - Hospitalized patients for bacterial keratitis in Ophthalmology Department, Clermont-Ferrand university hospital .with a controlled local infection after 48 hours local antibiotics.

    • with a corneal ulcer diameter > 2 millimeters

Exclusion Criteria:

  • - Ulcers deeper than the superficial stroma, perforated ulcers or pre-perforated, requiring a surgical intervention < 15 days.
  • Clinical suspicion and/or microbiological evidence of fungal or parasitic infection
  • Non controlled infection in spite of 48 hours intensive local antibiotics
  • Allergy
  • Silver or copper salts treatment
  • Ocular surgery within the last 1 month
  • Unable to follow up medical examinations for geographical, social, physical or psychological reasons
  • Patient already included in another clinical trial
  • Pregnant patients or breastfeeding
  • Person under a legal protection measure, under guardianship
  • Not cover by social insurance.

Sites / Locations

  • CHU de Clermont-FerrandRecruiting

Arms of the Study

Arm 1

Arm 2

Arm Type

Other

Experimental

Arm Label

Physiological salt solution

CACICOL20

Arm Description

The purpose of this study is to evaluate efficiency of CACICOL20 for bacterial keratitis. It is a double blinded comparison of epithelial defect in two groups of patients randomized between CACICOL20 and physiological salt solution.

The purpose of this study is to evaluate efficiency of CACICOL20 for bacterial keratitis. It is a double blinded comparison of epithelial defect in two groups of patients randomized between CACICOL20 and physiological salt solution.

Outcomes

Primary Outcome Measures

Epithelial corneal surface healing
each day, from date of randomization until the date of the complete corneal healing assessed to fifteen days, up to 2 months

Secondary Outcome Measures

Healing time of total corneal epithelial wound
each day, from date of randomization until the date of the complete corneal healing assessed to fifteen days, up to 2 months
Visual acuity
date of randomization and date of the complete corneal healing
Ulcer deep
every two days, from date of randomization until the date of the complete corneal healing assessed to fifteen days, up to 2 months
Healing keratitis rate
at the end of the study

Full Information

First Posted
November 25, 2013
Last Updated
December 16, 2013
Sponsor
University Hospital, Clermont-Ferrand
search

1. Study Identification

Unique Protocol Identification Number
NCT02016989
Brief Title
Matrix Therapy And Bacterial Keratitis
Acronym
CACICOL
Official Title
REGENERATING AGENT (OTR4120) AND BACTERIAL KERATITIS : A RANDOMISED TRIAL
Study Type
Interventional

2. Study Status

Record Verification Date
December 2013
Overall Recruitment Status
Unknown status
Study Start Date
November 2013 (undefined)
Primary Completion Date
September 2014 (Anticipated)
Study Completion Date
October 2014 (Anticipated)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor
Name of the Sponsor
University Hospital, Clermont-Ferrand

4. Oversight

5. Study Description

Brief Summary
The purpose of this study is to evaluate efficiency of CACICOL20 for bacterial keratitis. It is a double blinded comparison of epithelial defect in two groups of patients randomized between CACICOL20 and physiological salt solution.
Detailed Description
Extracellular matrix, composed of glycosaminoglycans (GAG) and matricial proteins, has a key role in tissular homeostasis. The matrix therapy is a new class of medical substance, called RGTAs, ReGeneraTing Agents, consist of chemically engineered polymers adapted to interact with and protect against proteolytic degradation of cytokines. OTR4120 (CACICOL20) is an heparan sulphate (HS) mimetic that can replace the degraded HS and protect and improve the bioavailability of cytokines. It aims to facilitate and potentiate the wound healing by restorating the natural microenvironment. CACICOL20 was used in treating corneal dystrophies and chronic corneal ulcers. It significantly favored corneal healing. It was well tolerated with no side effects. Bacterial keratitis is a serious ocular condition that may result in significant sight-threatening corneal sequelae. The common risk factors for infectious keratitis include ocular trauma, contact lens wear, recent ocular surgery, preexisting ocular surface disease, dry eyes, lid deformity, corneal sensational impairment, chronic use of topical steroids, and systemic immunosuppression. Serious cases of keratitis are hospitalized to administrate an intensive hospital-made local antibiotic. The purpose of this study is to evaluate efficiency of CACICOL20 for bacterial keratitis. It is a double blinded comparison of epithelial defect in two groups of patients randomized between CACICOL20 and physiological salt solution.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Bacterial Keratitis
Keywords
Bacterial keratitis, OTR4120, Matrix therapy

7. Study Design

Primary Purpose
Treatment
Study Phase
Not Applicable
Interventional Study Model
Parallel Assignment
Masking
ParticipantInvestigator
Allocation
Randomized
Enrollment
60 (Anticipated)

8. Arms, Groups, and Interventions

Arm Title
Physiological salt solution
Arm Type
Other
Arm Description
The purpose of this study is to evaluate efficiency of CACICOL20 for bacterial keratitis. It is a double blinded comparison of epithelial defect in two groups of patients randomized between CACICOL20 and physiological salt solution.
Arm Title
CACICOL20
Arm Type
Experimental
Arm Description
The purpose of this study is to evaluate efficiency of CACICOL20 for bacterial keratitis. It is a double blinded comparison of epithelial defect in two groups of patients randomized between CACICOL20 and physiological salt solution.
Intervention Type
Device
Intervention Name(s)
RGTA OTR4120 (CACICOL20)
Intervention Type
Device
Intervention Name(s)
physiological salt solution
Primary Outcome Measure Information:
Title
Epithelial corneal surface healing
Description
each day, from date of randomization until the date of the complete corneal healing assessed to fifteen days, up to 2 months
Time Frame
at day 1
Secondary Outcome Measure Information:
Title
Healing time of total corneal epithelial wound
Description
each day, from date of randomization until the date of the complete corneal healing assessed to fifteen days, up to 2 months
Time Frame
at day 1
Title
Visual acuity
Description
date of randomization and date of the complete corneal healing
Time Frame
at day 1 and day 12
Title
Ulcer deep
Description
every two days, from date of randomization until the date of the complete corneal healing assessed to fifteen days, up to 2 months
Time Frame
every day between day 0 to day 12
Title
Healing keratitis rate
Description
at the end of the study
Time Frame
at day 12

10. Eligibility

Sex
All
Minimum Age & Unit of Time
18 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: - Hospitalized patients for bacterial keratitis in Ophthalmology Department, Clermont-Ferrand university hospital .with a controlled local infection after 48 hours local antibiotics. with a corneal ulcer diameter > 2 millimeters Exclusion Criteria: - Ulcers deeper than the superficial stroma, perforated ulcers or pre-perforated, requiring a surgical intervention < 15 days. Clinical suspicion and/or microbiological evidence of fungal or parasitic infection Non controlled infection in spite of 48 hours intensive local antibiotics Allergy Silver or copper salts treatment Ocular surgery within the last 1 month Unable to follow up medical examinations for geographical, social, physical or psychological reasons Patient already included in another clinical trial Pregnant patients or breastfeeding Person under a legal protection measure, under guardianship Not cover by social insurance.
Central Contact Person:
First Name & Middle Initial & Last Name or Official Title & Degree
Patrick LACARIN
Phone
04 73 75 11 95
Email
placarin@chu-clermontferrand.fr
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Frédéric CHIAMBARETTA
Organizational Affiliation
University Hospital, Clermont-Ferrand
Official's Role
Principal Investigator
Facility Information:
Facility Name
CHU de Clermont-Ferrand
City
Clermont-Ferrand
ZIP/Postal Code
63003
Country
France
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Patrick LACARIN
Phone
04 73 75 11 95
Email
placarin@chu-clermontferrand.fr
First Name & Middle Initial & Last Name & Degree
Nicolas BONNIN

12. IPD Sharing Statement

Learn more about this trial

Matrix Therapy And Bacterial Keratitis

We'll reach out to this number within 24 hrs